Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 7/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | IDH1 | O75874 | 2/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | NRAS | P01111 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | CCNH | P51946 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24574159 | 1.00 | FLT3 (0.51) | FLT3IRAK4USP30IDH1CCNT1 | |
| SCHEMBL24574190 | 0.94 | FLT3 (0.51) | FLT3IRAK4USP30IDH1CCNT1 | |
| SCHEMBL24574149 | 0.92 | FLT3 (0.48) | FLT3IRAK4USP30IDH1CCNT1 | |
| SCHEMBL24574511 | 0.88 | FLT3 (0.53) | FLT3IRAK4USP30IDH1CCNT1 | |
| SCHEMBL19918240 | 0.87 | FLT3 (0.51) | FLT3IRAK4USP30IDH1CCNT1 | |
| SCHEMBL24574153 | 0.87 | FLT3 (0.49) | FLT3IRAK4USP30IDH1CCNT1 | |
| SCHEMBL24574586 | 0.87 | FLT3 (0.49) | FLT3IRAK4USP30IDH1CCNT1 | |
| SCHEMBL24574020 | 0.86 | FLT3 (0.49) | FLT3IRAK4USP30IDH1CCNT1 | |
| SCHEMBL24231686 | 0.86 | IRAK4 (0.62) | FLT3IRAK4USP30CCNT1NRAS | |
| SCHEMBL24574169 | 0.86 | USP30 (0.47) | FLT3IRAK4USP30IDH1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612410-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-04-28 | — | — | US | disclosed |
| US-20240294530-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2024-09-05 | — | — | US | disclosed |
| CN-117015380-A | Polycyclic IRAK and flt3 inhibiting compounds and uses thereof | 儿童医院医学中心 | 2023-11-07 | — | — | CN | disclosed |
| EP-4267142-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022140647-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140647-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294530-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | FLT3 1/4885IRAK4 5/4885USP30 1732/4885 |
| US-12612410-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | FLT3, IRAK3, IRAK2 | FLT3 1/4885IRAK4 5/4885USP30 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.